ACLX vs. IMCR, TWST, DNLI, VCEL, KYMR, CGON, APGE, SANA, SWTX, and RXRX
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Immunocore (IMCR), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Vericel (VCEL), Kymera Therapeutics (KYMR), CG Oncology (CGON), Apogee Therapeutics (APGE), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Immunocore received 2 more outperform votes than Arcellx when rated by MarketBeat users. However, 76.67% of users gave Arcellx an outperform vote while only 70.59% of users gave Immunocore an outperform vote.
Arcellx currently has a consensus target price of $78.73, indicating a potential upside of 49.13%. Immunocore has a consensus target price of $81.85, indicating a potential upside of 50.87%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Arcellx.
Arcellx has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Immunocore has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.
Immunocore has a net margin of -22.60% compared to Arcellx's net margin of -38.39%. Arcellx's return on equity of -13.11% beat Immunocore's return on equity.
In the previous week, Arcellx had 2 more articles in the media than Immunocore. MarketBeat recorded 28 mentions for Arcellx and 26 mentions for Immunocore. Arcellx's average media sentiment score of 0.54 beat Immunocore's score of 0.24 indicating that Arcellx is being referred to more favorably in the media.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Arcellx beats Immunocore on 10 of the 19 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
